Adverse Drug Events and Reactions Managed by Medical Toxicologists: an Analysis of the Toxicology Investigators Consortium (ToxIC) Registry, 2010–2016
- 79 Downloads
Adverse drug events/reactions (ADE/ADRs) cost more than $30 billion annually and are among the leading causes of death in the USA. Little is known about patients treated at the bedside for ADE/ADR by medical toxicologists.
We conducted a retrospective study of ADE/ADR cases reported to the Toxicology Investigators Consortium (ToxIC) registry between January 1, 2010, and December 31, 2016. Clinical and demographic data were collected including age, sex, circumstances surrounding exposure, suspected offending substance, clinical manifestations, treatment, disposition, and outcome.
Among 51,440 ToxIC cases during this time period, 673 ADE/ADR cases were reported (337 females). By age, ADE/ADRs were seen most commonly among adults age 19–65 years (442/673, 65.7% of ADE/ADR) and older adults age 65–89 years (134/673, 19.9% of ADE/ADR). 222/673 (33%) of consults for ADE/ADR were seen in the emergency department (ED); 181/673 (26.9%) were seen in the hospital ward; and 160/673 (23.8%) were seen in the intensive care unit (ICU). The most commonly reported sign for ADE/ADR was tachycardia: 51/673 (7.6%), followed by bradycardia: 49/673 (7.3%). Most commonly reported agents associated with ADE/ADR were as follows: 97/673 (14.4%) due to cardiovascular medications; 76/673 (11.3%) due to antipsychotic medications; and 61/673 (9.1%) due to antidepressants. 429/673 (63.7%) of ADE/ADR were reported as due to a single agent, and 212/673 (31.5%) were reported as due to multiple agents.
4.2% of cases managed at the bedside by a consulting toxicologist and reported to the ToxIC registry between 2010 and 2016 had ADE/ADR as the reason for consultation. Agents most commonly involved in ADE/ADRs included cardiovascular medications, antipsychotic medications, and antidepressants.
KeywordsAdverse drug reaction Adverse drug event Poisoning Drug safety
We acknowledge Stephen W. Dusza, DrPH, and Hope Kincaid, MPH, CPH, for their help with the statistical analysis. We thank Anita Kurt, PhD, RN, for managing all resources and operations related to this project. We thank the study team involved in ToxIC research at our institution: Rita M. Pechulis, MD; Richard Mazzaccaro, MD, PhD; Manuel F. Colon, BS; Amy Wier, DO; Gregory Makar, DO; Briana Tully, DO; Brittany Ely, DO; and Emily Pollack, MD.
Sources of Funding
This project was supported in part by an institutional Dorothy Rider Pool Trust for Health Research and Education Community Foundation Grant.
Compliance with Ethical Standards
ToxIC works under the approval of the Western Institutional Review Board (IRB) and participating sites obtain approval from their respective local IRB. This study was deemed non-human subjects research due to the characteristics of the data source and was therefore not subject to IRB review and approval.
Conflicts of Interest
- 1.World Health Organization. International drug monitoring: the role of national centres. Geneva: World Health Organization; 1972. (Technical Report Series No. 498)Google Scholar